In vitro spectrum of pexiganan activity when tested against pathogens from diabetic foot infections and with selected resistance mechanisms

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 3, 2015, Pages 1751-1754

  Flamm, Robert K ^a   Rhomberg, Paul R ^a   Simpson, Katie M ^a   Farrell, David J ^a   Sader, Helio S ^a   Jones, Ronald N ^a  

^a JMI LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAMASE; PEXIGANAN; VANCOMYCIN; ANTIINFECTIVE AGENT; ANTIMICROBIAL CATIONIC PEPTIDE;

ACINETOBACTER; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIUM ISOLATION; CITROBACTER KOSERI; DIABETIC FOOT INFECTION; ENTEROBACTER CLOACAE; ENTEROCOCCUS FAECIUM; ESCHERICHIA COLI; HUMAN; IN VITRO STUDY; INFECTION; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; PATHOGENESIS; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS; DIABETIC FOOT; DRUG EFFECTS; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; GRAM-NEGATIVE BACTERIAL INFECTIONS; GRAM-POSITIVE BACTERIAL INFECTIONS; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PROCEDURES;

ANTI-BACTERIAL AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; DIABETIC FOOT; DRUG RESISTANCE, BACTERIAL; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; GRAM-POSITIVE BACTERIA; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS;

EID: 84923234075     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.04773-14     Document Type: Article

References (13)

1. Hancock RE. 1997. Peptide antibiotics. Lancet 349:418-422.
2. Hancock RE, Falla T, Brown M. 1995. Cationic bactericidal peptides. Adv Microb Physiol 37:135-175.
3. Nicolas P, Mor A. 1995. Peptides as weapons against microorganisms in the chemical defense system of vertebrates. Annu Rev Microbiol 49:277-304.
4. Boman HG. 1995. Peptide antibiotics and their role in innate immunity. Annu Rev Immunol 13:61-92.
5. Yasin B, Harwig SS, Lehrer RI, Wagar EA. 1996. Susceptibility of Chlamydia trachomatis to protegrins and defensins. InfectImmun64:709-713.
6. Lipsky BA, Berendt AR, Cornia PB, Pile JC, Peters EJ, Armstrong DG, Deery HG, Embil JM, Joseph WS, Karchmer AW, Pinzur MS, Senneville E, Infectious Diseases Society of America. 2012. 2012 Infectious Diseases Society of America clinical practice guideline for the diagnosis and treatment of diabetic foot infections. Clin Infect Dis 54:e132-e173. http://dx.doi.org/10.1093/cid/cis346.
7. Saltoglu N, Dalkiran A, Tetiker T, Bayram H, Tasova Y, Dalay C, Sert M. 2010. Piperacillin/tazobactam versus imipenem/cilastatin for severe diabetic foot infections: a prospective, randomized clinical trial in a university hospital. Clin Microbiol Infect 16:1252-1257. http://dx.doi.org/10.1111/j.1469-0691.2009.03067.x.
8. Ge Y, MacDonald D, Henry MM, Hait HI, Nelson KA, Lipsky BA, Zasloff MA, Holroyd KJ. 1999. In vitro susceptibility to pexiganan of bacteria isolated from infected diabetic foot ulcers. Diagn Microbiol Infect Dis 35:45-53.
9. Ge Y, MacDonald DL, Holroyd KJ, Thornsberry C, Wexler H, Zasloff M. 1999. In vitro antibacterial properties of pexiganan, an analog of magainin. Antimicrob Agents Chemother 43:782-788.
10. Fuchs PC, Barry AL, Brown SD. 1998. In vitro antimicrobial activity of MSI-78, a magainin analog. Antimicrob Agents Chemother 42:1213-1216.
11. Clinical and Laboratory Standards Institute. 2012. M07-A9. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard: ninth edition. Clinical and Laboratory Standards Institute, Wayne, PA.
12. Clinical and Laboratory Standards Institute. 2014. M100-S24. Performance standards for antimicrobial susceptibility testing: 24th informational supplement. Clinical and Laboratory Standards Institute, Wayne, PA.
13. Falla TJ, Karunaratne DN, Hancock RE. 1996. Mode of action of the antimicrobial peptide indolicidin. J Biol Chem 271:19298-19303.